Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners

DISCUSSION: Recent consensus advice on the care of patients with FH in Australia provides an opportunity for GPs to increase their awareness and skills in diagnosing and managing FH. New Medicare Benefits Schedule items for genetic testing and Pharmaceutical Benefits Scheme listing for the use of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors offer GPs additional supports to improve the care of patients with FH. A shared-care approach between GPs and non-GP specialists with expertise in multiple disciplines offers the best option to facilitate genetic testing and management of index cases and affected family relatives. Implementation of this guidance in the primary care setting remains an ongoing challenge and needs to be embraced as a high priority.PMID:34462766 | DOI:10.31128/AJGP-02-21-5836

Source: Australian Family Physician - August 31, 2021 Category: Primary Care Authors: Tom Brett Jan Radford Clare Heal Charlotte Mary Hespe Jacquie Garton-Smith Andrew Kirke Dick C Chan Jing Pang Gerald F Watts Source Type: research